EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression

Yohei Masugi iD, Manabu Takamatsu, Mariko Tanaka, Kensuke Hara, Yosuke Inoue, Tsuyoshi Hamada iD, Tatsunori Suzuki, Junichi Arita, Yuki Hirose, Yoshikuni Kawaguchi, Yousuke Nakai, Atsushi Oba und 13 weitere

The Journal of Pathology: Clinical Research · 2023-09 · 9 (5) · 339-353

DOI: 10.1002/cjp2.323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 08.06.2023. Verfasst von Yohei Masugi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiwa Securities Health Foundation, Japan Society for the Promotion of Science, Pancreas Research Foundation of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alterations in KRAS , CDKN2A ( p16 ), TP53 , and SMAD4 genes have been major drivers of pancreatic carcinogenesis. The clinical course of patients with pancreatic cancer in relation to these driver alterations has not been fully characterised in large populations. We hypothesised that pancreatic carcinomas with different combinations of KRAS mutation and aberrant expression of CDKN2A, p53, and SMAD4 might show distinctive recurrence patterns and post‐operative survival outcomes. To test this hypothesis, we utilised a multi‐institutional cohort of 1,146 resected pancreatic carcinomas and assessed KRAS mutations by droplet digital polymerase chain reaction and CDKN2A, p53, and SMAD4 expression by immunohistochemistry. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for disease‐free survival (DFS) and overall survival (OS) were computed according to each molecular alteration and the number of altered genes using the Cox regression models. Multivariable competing risks regression analyses were conducted to assess the associations of the number of altered genes with specific patterns of recurrence. Loss of SMAD4 expression was associated with short DFS (multivariable HR, 1.24; 95% CI, 1.09–1.43) and OS times (multivariable HR, 1.27; 95% CI, 1.10–1.46). Compared to cases with 0–2 altered genes, cases with three and four altered genes had multivariable HRs for OS of 1.28 (95% CI, 1.09–1.51) and 1.47 (95% CI, 1.22–1.78), respectively ( p trend < 0.001). Patients with an increasing number of altered genes were more likely to have short DFS time ( p trend = 0.003) and to develop liver metastasis ( p trend = 0.006) rather than recurrence at local or other distant sites. In conclusion, loss of SMAD4 expression and an increasing number of altered genes were associated with unfavourable outcomes in pancreatic cancer patients. This study suggests that the accumulation of the four major driver alterations can confer a high metastatic potential to the liver, thereby impairing post‐operative survival among patients with pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinomaHumansTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)MutationSmad4 ProteinCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

cohort studiesoncogenesoutcomepancreatectomypancreatic ductal adenocarcinoma

Substanzen

Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)SMAD4 protein, humanSmad4 ProteinKRAS protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

ORCID-Profile: Yohei Masugi, Tsuyoshi Hamada

Förderung

  • Daiwa Securities Health Foundation
  • Japan Society for the Promotion of Science
  • Pancreas Research Foundation of Japan
  • Takeda Science Foundation

Zitieren

APA

Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., Nakai, Y., Oba, A., Sasahira, N., Shimane, G., Takeda, T., Tateishi, K., Uemura, S., Fujishiro, M., Hasegawa, K., …, & GTK Pancreatic Cancer Study Group in Japan (2023). Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression. The Journal of Pathology: Clinical Research, 9(5), 339-353. https://doi.org/10.1002/cjp2.323

Vancouver

Masugi Y, Takamatsu M, Tanaka M, Hara K, Inoue Y, Hamada T, et al. Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression. The Journal of Pathology: Clinical Research. 2023;9(5):339-353. doi:10.1002/cjp2.323

BibTeX
@article{Masugi2023,
  author = {Masugi, Yohei and Takamatsu, Manabu and Tanaka, Mariko and Hara, Kensuke and Inoue, Yosuke and Hamada, Tsuyoshi and Suzuki, Tatsunori and Arita, Junichi and Hirose, Yuki and Kawaguchi, Yoshikuni and Nakai, Yousuke and Oba, Atsushi and Sasahira, Naoki and Shimane, Gaku and Takeda, Tsuyoshi and Tateishi, Keisuke and Uemura, Sho and Fujishiro, Mitsuhiro and Hasegawa, Kiyoshi and Kitago, Minoru and Takahashi, Yu and Ushiku, Tetsuo and Takeuchi, Kengo and Sakamoto, Michiie and GTK Pancreatic Cancer Study Group in Japan, GTK Pancreatic Cancer Study Group in Japan},
  title = {Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  volume = {9},
  number = {5},
  pages = {339--353},
  doi = {10.1002/cjp2.323}
}
Kostenlos starten →